-
EP3443006
European procedure
Extract from the Register of European Patents
EP About this file: EP3443006
| EP3443006 - TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 07.06.2024 Database last updated on 31.01.2025 | |
| Former | The patent has been granted Status updated on 30.06.2023 | ||
| Former | Grant of patent is intended Status updated on 22.02.2023 | ||
| Former | Examination is in progress Status updated on 27.01.2023 | ||
| Former | Grant of patent is intended Status updated on 14.11.2022 | ||
| Former | Examination is in progress Status updated on 15.01.2021 | ||
| Former | Request for examination was made Status updated on 18.01.2019 | ||
| Former | The international publication has been made Status updated on 20.10.2017 | ||
| Former | unknown Status updated on 05.07.2017 | Most recent event Tooltip | 22.11.2024 | Lapse of the patent in a contracting state New state(s): MC | published on 25.12.2024 [2024/52] | Applicant(s) | For all designated states SANOFI 46 avenue de la Grande Armée 75017 Paris / FR | [2023/29] |
| Former [2019/08] | For all designated states Sanofi 54 Rue de la Boetie 75008 Paris / FR | Inventor(s) | 01 /
YANG, Zhi-Yong c/o Sanofi 55 Corporate Drive Mail Code 55A-505A Bridgewater NJ 08807 / US | 02 /
NABEL, Gary, J. c/o Sanofi 55 Corporate Drive Mail Code 55A-505A Bridgewater NJ 08807 / US | 03 /
WU, Lan c/o Sanofi 55 Corporate Drive Mail Code 55A-505A Bridgewater NJ 08807 / US | 04 /
SEUNG, Edward c/o Sanofi 55 Corporate Drive Mail Code 55A-505A Bridgewater NJ 08807 / US | 05 /
WEI, Ronnie c/o Sanofi 55 Corporate Drive Mail Code 55A-505A Bridgewater NJ 08807 / US | 06 /
BENINGA, Jochen c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | 07 /
RAO, Ercole c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | 08 /
LEUSCHNER, Wulf Dirk c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | 09 /
BEIL, Christian c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | 10 /
LANGE, Christian c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | 11 /
CORVEY, Carsten c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt Am Main / DE | [2019/08] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [2023/31] |
| Former [2019/08] | Lavoix Bayerstrasse 83 80335 München / DE | Application number, filing date | 17732263.3 | 13.04.2017 | [2019/08] | WO2017US27488 | Priority number, date | US201662322036P | 13.04.2016 Original published format: US 201662322036 P | US201662331191P | 03.05.2016 Original published format: US 201662331191 P | US201662412187P | 24.10.2016 Original published format: US 201662412187 P | EP20170305298 | 17.03.2017 Original published format: EP 17305298 | [2019/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2017180913 | Date: | 19.10.2017 | Language: | EN | [2017/42] | Type: | A2 Application without search report | No.: | EP3443006 | Date: | 20.02.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.10.2017 takes the place of the publication of the European patent application. | [2019/08] | Type: | B1 Patent specification | No.: | EP3443006 | Date: | 02.08.2023 | Language: | EN | [2023/31] | Search report(s) | International search report - published on: | EP | 08.02.2018 | Classification | IPC: | C07K16/24, C07K16/28, C07K16/32, A61P35/00, A61K39/00, A61P29/00 | [2022/46] | CPC: |
C07K16/2818 (EP,EA,IL,KR,US);
C07K16/468 (EA,IL,KR,US);
C07K16/241 (EP,EA,IL,KR,US);
A61K39/3955 (EA,IL,KR,US);
A61K39/39558 (EA,IL,KR,US);
A61K45/06 (EA,IL,KR,US);
A61P29/00 (EP,IL);
A61P35/00 (EP,IL);
C07K1/22 (EA,IL,KR,US);
C07K16/244 (EP,EA,IL,KR,US);
C07K16/247 (EP,EA,IL,KR,US);
C07K16/2803 (EP,EA,IL,KR,US);
C07K16/2809 (EP,EA,IL,KR,US);
C07K16/2887 (EP,EA,IL,KR,US);
C07K16/2896 (EP,EA,IL,KR,US);
C07K16/32 (EP,EA,IL,KR,US);
A61K2039/505 (EP,EA,IL,KR,US);
C07K2317/31 (EP,EA,IL,KR,US);
C07K2317/35 (EP,EA,IL,US);
C07K2317/52 (EP,EA,IL,KR,US);
C07K2317/526 (EA,IL,KR,US);
C07K2317/56 (EP,EA,IL,KR,US);
C07K2317/565 (EA,IL,KR,US);
C07K2317/64 (EP,EA,IL,KR,US);
C07K2317/73 (EP,EA,IL,KR,US);
C07K2317/75 (EP,EA,IL,KR,US);
C07K2317/76 (EP,EA,IL,KR,US);
|
| Former IPC [2019/08] | C07K16/24, C07K16/28, C07K16/32, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/08] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | 12.11.2018 | Title | German: | TRISPEZIFISCHE UND/ODER DREIWERTIGE BINDUNGSPROTEINE | [2019/08] | English: | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | [2019/08] | French: | PROTÉINES DE LIAISON TRISPÉCIFIQUES ET/OU TRIVALENTES | [2019/08] | Entry into regional phase | 12.11.2018 | National basic fee paid | 12.11.2018 | Designation fee(s) paid | 12.11.2018 | Examination fee paid | Examination procedure | 12.11.2018 | Examination requested [2019/08] | 12.11.2018 | Date on which the examining division has become responsible | 07.06.2019 | Amendment by applicant (claims and/or description) | 19.01.2021 | Despatch of a communication from the examining division (Time limit: M04) | 16.03.2021 | Reply to a communication from the examining division | 13.07.2021 | Despatch of a communication from the examining division (Time limit: M04) | 09.09.2021 | Reply to a communication from the examining division | 15.11.2022 | Communication of intention to grant the patent | 26.01.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 23.02.2023 | Communication of intention to grant the patent | 21.06.2023 | Fee for grant paid | 21.06.2023 | Fee for publishing/printing paid | 21.06.2023 | Receipt of the translation of the claim(s) | Divisional application(s) | EP23179697.0 / EP4257193 | Opposition(s) | 03.05.2024 | No opposition filed within time limit [2024/28] | Fees paid | Renewal fee | 15.04.2019 | Renewal fee patent year 03 | 31.03.2020 | Renewal fee patent year 04 | 15.04.2021 | Renewal fee patent year 05 | 20.03.2022 | Renewal fee patent year 06 | 14.03.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | LV | 02.08.2023 | MC | 02.08.2023 | SM | 02.08.2023 | IS | 02.12.2023 | [2024/52] |
| Former [2024/20] | LV | 02.08.2023 | |
| SM | 02.08.2023 | ||
| IS | 02.12.2023 | ||
| Former [2024/10] | LV | 02.08.2023 | |
| IS | 02.12.2023 | Cited in | International search | [Y]EP1378520 (INST GENETICS CAS [CN], et al); | [Y]EP1736484 (BEIJING ABT GENETIC ENGINEERIN [CN], et al); | [A]WO2009149189 (ABBOTT LAB [US], et al); | [A]US2010226923 (RAO ERCOLE [DE], et al); | [Y]WO2011154453 (GENMAB AS [DK], et al); | [YD]WO2012135345 (SANOFI SA [FR], et al); | [Y]WO2014116846 (ABBVIE INC [US]); | [A]US2014213772 (GHAYUR TARIQ [US], et al); | [Y]WO2014144299 (ABBVIE INC [US]); | [Y]WO2015149077 (XENCOR INC [US]); | [ADP]WO2016116626 (SANOFI SA [FR]); | [E]WO2017074878 (SANOFI SA [FR], et al); | by applicant | WO9627011 | WO9951642 | WO2012135345 | WO2016116626 |